# A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

> **NCT06600321** · PHASE1 · RECRUITING · sponsor: **Alnylam Pharmaceuticals** · enrollment: 158 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma

## Interventions

- **DRUG:** ALN-BCAT
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06600321
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-10-31
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06600321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06600321, "A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06600321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*